虚拟现实技术治疗抑郁障碍患者认知功能改善的研究

Improvement of Cognitive Function in Patients with Depressive Disorders Treated with Virtual Reality Technology

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2023, 50(6)
作者
作者单位

武汉市精神卫生中心 ;

摘要
目的:分析评价虚拟现实技术治疗抑郁障碍患者的临床疗效及认知功能改善情况。方法:将118例符合ICD-10抑郁障碍诊断标准的患者随机分为VR治疗联合药物治疗组(n=58)和常规药物治疗组(n=60),进行为期8周的临床观察。使用临床疗效总评量表(CGI- GI)和汉密尔顿抑郁量表(HAMD)分别在基线、4周末和8周末评估有效率和临床治疗效果。在基线和8周末评定MMCB评价认知功能改善状况。使用药物不良反应量表(TESS)评价安全性。结果:基线时两组一般资料无显著差异。8周末治疗组和对照组有效率分别为91.38%和90.00%,两组比较P=0.676,无统计学意义。基线时两组汉密尔顿抑郁量表(HAMD)评分无统计学差异(P>0.05),第4周末、第8周末两组间比较差异有统计学意义(t=2.325,P=0.022;t=2.682,P=0.008)。治疗前两组间MCCB评分无统计学差异(P>0.05),治疗后MCCB评分两组在注意/警觉性、视觉学习、社会认知、总认知4个维度有统计学差异(P<0.05)。两组均未见严重不良反应,不良事件组间发生率无统计学差异(X2/Z=0.210,p=0.647) 。结论:VR治疗联合药物治疗对于抑郁障碍有一定疗效,安全性高;可以在一定程度上改善患者的认知功能。
Abstract
OBJECTIVE: To analyze and evaluate the clinical efficacy and cognitive function improvement of virtual reality technology in treating patients with depressive disorders. Methods: 118 patients who met the ICD-10 diagnostic criteria for depressive disorders were randomly divided into the VR treatment combined with medication group (n=58) and the conventional medication group (n=60) for an 8-week clinical observation. Efficacy and clinical treatment effects were assessed using the Clinical General Index of Effectiveness (CGI- GI) and Hamilton Depression Scale (HAMD) at baseline, end of 4 and end of 8 weeks, respectively. The MMCB was assessed at baseline and at the end of 8 weekends to evaluate improvement in cognitive function. Safety was evaluated using the Trial Adverse Substance Scale (TESS). RESULTS: There was no significant difference in the general information between the two groups at baseline. the effective rates at the end of 8 weekends were 91.38% and 90.00% in the treatment and control groups, respectively. p=0.676 for comparison of the two groups, which was not statistically significant. There was no statistically significant difference in Hamilton Depression Scale (HAMD) scores between the two groups at baseline (P>0.05), and the difference between the two groups at the end of the 4th and 8th weekends was statistically significant (t=2.325, P=0.022; t=2.682, P=0.008). There was no statistically significant difference in MCCB scores between the two groups before treatment (P>0.05), and there was a statistically significant difference in MCCB scores between the two groups after treatment in the four dimensions of attention/alertness, visual learning, social cognition, and total cognition (P<0.05). No serious adverse reactions were seen in both groups, and the incidence of adverse events was not statistically different between groups (X2/Z=0.210, p=0.647). CONCLUSION: VR therapy combined with medication is effective and safe for depressive disorders; it can improve patients cognitive function to a certain extent.
关键词
抑郁障碍;虚拟现实技术;认知功能
基金项目
页码 1347-1350
  • 参考文献
  • 相关文献
  • 引用本文

王朔*. 虚拟现实技术治疗抑郁障碍患者认知功能改善的研究 [J]. 国际精神病学杂志. 2023; 50; (6). 1347 - 1350.

  • 文献评论

相关学者

相关机构